Touchlight Highlights Cell-Free DNA Platform Targeting Gene and mRNA Therapy Demand

According to a recent LinkedIn post from Touchlight, the company is promoting its cell-free DNA platform as an alternative to plasmid DNA, highlighting rapid production, easy scale-up, flexible deployment, and reduced risk of bacterial impurities. The post positions the dbDNA™ technology as suited for gene therapies, mRNA vaccines, and cell-based treatments across the development lifecycle from discovery to commercialization.

The emphasis on speed, purity, and scalability suggests Touchlight is targeting pain points in current DNA supply chains, an area of increasing importance as cell and gene therapy pipelines expand. For investors, this focus may indicate a strategy to capture value in enabling technologies for advanced therapeutics, potentially enhancing Touchlight’s relevance as a partner or supplier to biopharma companies seeking more reliable DNA manufacturing solutions.